Video from ECR 2014: Interview with ECR President Dr. Valentin Sinitsyn

Mar 6, 2014

2014 03 06 22 29 06 572 2014 03 06 Sinitsyn Video

VIENNA - ECR 2014 President Dr. Valentin Sinitsyn, PhD, a professor and the head of the radiology department at the Federal Center of Medicine and Rehabilitation in Moscow, talks about the new changes at this year's congress with AuntMinnieEurope.com Editor-in-Chief Philip Ward. He also discusses how the political situation in Ukraine is affecting the congress, but notes that the ECR helps to strengthen friendship and understanding between radiologists from many nations.

Preloader Anim

Interview with ECR 2014 President Dr. Valentin Sinitsyn, PhD, from Moscow.

Video produced by Christof. G. Pelz I GRAFIFANT Creation. Grafik. Photo I www.grafifant.at

Cardiac stress test imaging comparison showing DeepAC and CT-based attenuation correction scans for two patients with quantitative perfusion data.

AI-driven cardiac PET attenuation correction shows promise

June 3, 2026

Preablation, postablation, and recurrence multiparametric MRI scans depict a 63-year-old man treated with transperineal focal laser ablation (TPLA) for localized prostate cancer. Clinical parameters included an initial prostate-specific antigen (PSA) level of 7.2 ng/mL, a Prostate Imaging Reporting and Data System (PI-RADS) grade 4 lesion (red circles) in the right apical peripheral zone, and a maximum tumor length of 5 mm. MRI-guided targeted biopsy confirmed a Gleason score 3+4 prostate cancer tumor. (A) Pre-ablation axial T2-weighted MRI scan and apparent diffusion coefficient (ADC) image shows the apical PI-RADS 4 lesion (circles). (B) Six-month post-ablation axial T2-weighted MRI scan and ADC image show cystic necrosis (arrows). There was no evidence of recurrence; the PSA level was 1.5 ng/mL. (C) One-year after ablation, the patient’s PSA level had increased to 4.3 ng/mL. Axial T2-weighted MRI scan and the ADC image shows a recurrent lesion (blue circles) in the right apical peripheral zone adjacent to the ablation scar. Targeted biopsy confirmed Gleason score 3+4 prostate cancer, which was classified as in-field recurrence of clinically significant prostate cancer and subsequently re-treated with TPLA. In summary, serial multiplanar MRI demonstrates treatment response after TPLA with post-ablation necrosis, followed by MRI-detected IFR confirmed with biopsy at 12-month follow-up. Multiparametric MRI was performed with a 3.0-T MRI scanner (Skyra; Siemens Healthineers) using T2-weighted, diffusion-weighted, and ADC sequences, with gadobenate dimeglumine contrast material administration (Bracco Diagnostics).

Image-guided focal laser ablation effective for prostate cancer

June 3, 2026

ASCO: With help from AI, interventions boost lung cancer screening

June 3, 2026

2260299 Philips 01 Aunt Minnie Leadgen Newsletter Banner 300x250 Static

Philips Interactive Multimedia Reporting: Where Insight Meets Impact

June 2, 2026

AI-driven cardiac PET attenuation correction shows promise

By Kate Madden Yee

The algorithm could offer a “practical alternative in cardiac PET,” researchers noted.

June 3, 2026

Cardiac stress test imaging comparison showing DeepAC and CT-based attenuation correction scans for two patients with quantitative perfusion data.

Image-guided focal laser ablation effective for prostate cancer

By Amerigo Allegretto

MRI-directed, ultrasound-guided TPLA may be a promising technique to treat prostate cancer while avoiding radical therapies.

June 3, 2026

Preablation, postablation, and recurrence multiparametric MRI scans depict a 63-year-old man treated with transperineal focal laser ablation (TPLA) for localized prostate cancer. Clinical parameters included an initial prostate-specific antigen (PSA) level of 7.2 ng/mL, a Prostate Imaging Reporting and Data System (PI-RADS) grade 4 lesion (red circles) in the right apical peripheral zone, and a maximum tumor length of 5 mm. MRI-guided targeted biopsy confirmed a Gleason score 3+4 prostate cancer tumor. (A) Pre-ablation axial T2-weighted MRI scan and apparent diffusion coefficient (ADC) image shows the apical PI-RADS 4 lesion (circles). (B) Six-month post-ablation axial T2-weighted MRI scan and ADC image show cystic necrosis (arrows). There was no evidence of recurrence; the PSA level was 1.5 ng/mL. (C) One-year after ablation, the patient’s PSA level had increased to 4.3 ng/mL. Axial T2-weighted MRI scan and the ADC image shows a recurrent lesion (blue circles) in the right apical peripheral zone adjacent to the ablation scar. Targeted biopsy confirmed Gleason score 3+4 prostate cancer, which was classified as in-field recurrence of clinically significant prostate cancer and subsequently re-treated with TPLA. In summary, serial multiplanar MRI demonstrates treatment response after TPLA with post-ablation necrosis, followed by MRI-detected IFR confirmed with biopsy at 12-month follow-up. Multiparametric MRI was performed with a 3.0-T MRI scanner (Skyra; Siemens Healthineers) using T2-weighted, diffusion-weighted, and ADC sequences, with gadobenate dimeglumine contrast material administration (Bracco Diagnostics).

ASCO: With help from AI, interventions boost lung cancer screening

By Erik L. Ridley

Screening rate increased sharply over six years at the 17-hospital health system.

June 3, 2026

Philips Interactive Multimedia Reporting: Where Insight Meets Impact

By Philips Healthcare Informatics

Radiology is no longer just about what you see, it’s about how effectively you communicate it.

June 2, 2026

2260299 Philips 01 Aunt Minnie Leadgen Newsletter Banner 300x250 Static

Radiologists estimate time savings with advanced radiology reports

Survey-driven insights into the impact of interactive multimedia reporting, plus practical tips to take forward when planning to implement a system.

June 2, 2026

David Vining Md Anderson Longitudinal Record Imr 2026

Interactive multimedia radiology reporting improves physician consults

Radiologists and referring physicians who are successfully using IMR advanced radiology reporting share their perspectives.

June 2, 2026

Adobe Stock 1568461586 Fizkes

SNMMI: PET reveals new brain activity in multiple sclerosis

Understanding how and where certain brain connections are lost can help explain the symptoms patients experience.

June 2, 2026

Representative SV2A PET images comparing synaptic density in healthy and disease states. The left panel shows F-18 SynVesT-1 PET distribution volume (VT) maps of the brain and spinal cord in a naïve control mouse and a mouse with experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis. The right panel shows Cu-11 UCB-J PET images of the brain of a 46-year-old male healthy control (left) and 43-year-old female MS patient (right).

SNMMI: New PET platform guides real-time bone cancer margin assessment

By Kate Madden Yee

The approach has the potential to reshape surgical practice for osteosarcoma by allowing for precise tumor resection.

June 2, 2026

(A-C) Representative whole-body maximum-intensity projection images and regional fused PET/CT images from three histologically confirmed osteosarcoma patients who underwent paired [68Ga]Ga-B7-H3-BCH PET/CT and 18F-FDGE PET/CT within seven days. (D) Multimodal imaging evaluation of Patient Three, including x-ray, MRI (T2-weighted imaging, T2WI), CT, and B7-H3 PET/CT.

AI approach could improve DBT efficiency

By Amerigo Allegretto

AI-based slab reconstruction may help improve screening DBT workflows while not compromising on image quality.

June 2, 2026

Slab reconstruction provides visualization of subtle architectural distortion similar to that of standard 1-mm slices in a false-positive screening exam. Images include breast exams from a 45-year-old woman who underwent screening mammography. Craniocaudal tomosynthesis images with (A) 1-mm slices and (B) 6-mm slab reconstructions show an area of architectural distortion in the subareolar region of the left breast (arrow). (C) Targeted ultrasound imaging shows a corresponding irregular hypoechoic mass (arrow), which was subsequently biopsied. Pathologic examination revealed a sclerosing papillary lesion.

SNMMI: Incoming president talks meeting highlights, previews next year

By Kate Madden Yee

AuntMinnie.com interviewed incoming SNMMI president Heather Jacene, MD.

June 2, 2026

Heather Jacene, MD

SNMMI: Biomarkers predict I-131 response in obese thyroid cancer patients

By Kate Madden Yee

Metabolic status should be considered in post-therapy evaluation of obese differentiated thyroid cancer patients, researchers noted.

June 2, 2026

Podcast: Telltale signs your MRI safety standards are inadequate

Check your MRI safety sense.

June 2, 2026

The Invisible Force Podcast Album Cover Auntminnie Jan 2026 Thumbnails

Page 1 of 231